Jun 12 |
Lantern Pharma Receives Certificate of Patent from Japanese Patent Office (JPO) for Composition of Matter Covering Drug Candidate LP-284
|
May 24 |
Lantern Pharma files for $150M mixed shelf offering
|
May 14 |
LTRN: Expanding Horizons into Asia
|
May 9 |
Lantern Pharma GAAP EPS of -$0.51 misses by $0.08
|
May 9 |
Lantern Pharma Reports First Quarter 2024 Financial Results and Business Highlights
|
May 6 |
Lantern Pharma and Oregon partner to develop cancer treatment
|
May 6 |
Oregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of First-In-Class Drug Candidate XCE853 – A Potent Inhibitor of Cancer Metabolism
|
May 2 |
Lantern Pharma to Report First Quarter 2024 Operating & Financial Results on May 9th, 2024 at 4:30 p.m. ET
|
Apr 24 |
Lantern Pharma Launches "Webinar Wednesdays" Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug Development
|
Apr 22 |
Lantern Pharma Receives Regulatory Approval to Expand Harmonicâ„¢ Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan
|